Vascular & Endovascular

This channel includes news on non-coronary vascular disease and therapies. These include peripheral artery disease (PAD), abdominal and thoracic aortic aneurysm (AAA and TAA), aortic dissection, pulmonary embolism (PE), critical limb ischemia (CLI), carotid artery and stroke interventions, venous interventions, deep vein thrombosis (DVT), and interventional radiology therapies. The focus on most of these therapies is minimally invasive, catheter-based procedures performed in a cath lab.

Pollution

Air pollution linked to 8.8M deaths each year—most due to CVD

Air pollution could be contributing to twice as many deaths as previously estimated, according to research published in the European Heart Journal. Cardiovascular disease often deals the final blow, with CVD events accounting for 40 to 80 percent of these deaths.

March 13, 2019

Bleeding monitoring system for endovascular procedures gains FDA approval

The Early Bird Bleed Monitoring System, which can detect internal bleeding during endovascular procedures, has been granted de novo classification by the FDA. The approval was announced March 5 by Saranas, the device’s manufacturer.

March 6, 2019

Stroke risk factors, prevalence worse in rural areas

Despite living in a country with universal healthcare, Canadians residing in rural areas have more vascular risk factors and a higher incidence of stroke, even after adjusting for comorbidities and sociodemographic conditions.

March 4, 2019

Study finds thrombectomy safe for childhood stroke victims

A small-scale study out of Germany has concluded thrombectomy—an already proven treatment for large intracranial vessel occlusions in adults—is also safe in children.

February 27, 2019

When should stroke thrombectomy be considered futile?

When endovascular thrombectomy procedures for acute ischemic stroke take more than an hour or require more than three attempts to remove the clot, outcomes significantly worsen, according to a study published Feb. 25 in the Journal of the American College of Cardiology.

February 26, 2019

FDA: Higher doses of tofacitinib tied to increased risks of death, pulmonary embolism

The FDA issued a safety alert Feb. 25 warning that a 10 mg, twice-daily dose of tofacitinib—sold under the brand names Xeljanz and Xeljanz XR—has been linked to an increased risk of pulmonary embolism and death in patients with rheumatoid arthritis. That dose is only approved for patients with ulcerative colitis, the agency said.

February 26, 2019
Cheryl Petersilge, MD, MBA, with the department of regional radiology at the Cleveland Clinic, examined enterprise imaging—and how radiologists must integrate and collaborate with other departments. Her clinical perspective clinical perspective was published online in the October issue of the American Journal of Roentgenology.

‘Inadvertently reversed’ mortality data further muddy debate on paclitaxel PAD treatments

In the latest twist in the debate over the long-term safety of paclitaxel-coated balloons and stents, a correction published Feb. 19 in Circulation said the five-year mortality results of the Zilver PTX randomized trial were “inadvertently reversed”—and that uncoated devices were actually associated with better survival. 

February 20, 2019

Startup selling blood from young donors crumbles under FDA scrutiny

A startup that sold young donors’ blood to consumers in several states with the goal of treating conditions such as dementia, Alzheimer’s disease and heart disease has apparently shut down in the wake of an FDA statement that the blood-infusion technique has no scientific merit.

February 20, 2019

Around the web

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Kate Hanneman, MD, explains why many vendors and hospitals want to lower radiology's impact on the environment. "Taking steps to reduce the carbon footprint in healthcare isn’t just an opportunity," she said. "It’s also a responsibility."

Trimed Popup
Trimed Popup